MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
- 1 October 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 9 (10) , 1135-1141
- https://doi.org/10.1586/erv.10.111
Abstract
(2010). MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Review of Vaccines: Vol. 9, No. 10, pp. 1135-1141. doi: 10.1586/erv.10.111Keywords
This publication has 56 references indexed in Scilit:
- The Adjuvant MF59: A 10-Year PerspectivePublished by Springer Nature ,2003
- Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in miceVaccine, 1999
- Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59Vaccine, 1995
- Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvantVaccine, 1993
- Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulationVaccine, 1990
- Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunityVaccine, 1987
- Sterol, Structure and Membrane FunctionCritical Reviews in Biochemistry, 1983
- New Metabolizable Immunologic Adjuvant for Human UseNew England Journal of Medicine, 1967
- Antigenicity of Soluble Protein in the Presence of High Levels of Antibody : a Possible Mode of Action of the Antigen AdjuvantsNature, 1966
- New Metabolizable Immunologic Adjuvant for Human UseNew England Journal of Medicine, 1964